The study, sponsored by Centinel Spine, will include patients ages 18 to 69 who have a diagnosis of radiculopathy or myelopathy with radiculopathy, according to a June 1 news release. About 390 patients will be enrolled in the trial.
Centinel Spine’s Prodisc C and Prodisc C Vivo will be compared with Zimmer Biomet’s Mobi C disc in the study.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
